175 related articles for article (PubMed ID: 27074458)
1. Assessment of radiobiological metrics applied to patient-specific QA process of VMAT prostate treatments.
Clemente-Gutiérrez F; Pérez-Vara C; Clavo-Herranz MH; López-Carrizosa C; Pérez-Regadera J; Ibáñez-Villoslada C
J Appl Clin Med Phys; 2016 Mar; 17(2):341-367. PubMed ID: 27074458
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric and radiobiological comparison of prostate VMAT plans optimized using the photon and progressive resolution algorithm.
Chow JCL; Jiang R; Xu L
Med Dosim; 2020 Spring; 45(1):14-18. PubMed ID: 31103251
[TBL] [Abstract][Full Text] [Related]
3. Novel Radiobiological Gamma Index for Evaluation of 3-Dimensional Predicted Dose Distribution.
Sumida I; Yamaguchi H; Kizaki H; Aboshi K; Tsujii M; Yoshikawa N; Yamada Y; Suzuki O; Seo Y; Isohashi F; Yoshioka Y; Ogawa K
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):779-86. PubMed ID: 25936816
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric validation and clinical implementation of two 3D dose verification systems for quality assurance in volumetric-modulated arc therapy techniques.
Clemente-Gutiérrez F; Pérez-Vara C
J Appl Clin Med Phys; 2015 Mar; 16(2):5190. PubMed ID: 26103189
[TBL] [Abstract][Full Text] [Related]
5. Comparison of DVH-based plan verification methods for VMAT: ArcCHECK-3DVH system and dynalog-based dose reconstruction.
Saito M; Kadoya N; Sato K; Ito K; Dobashi S; Takeda K; Onishi H; Jingu K
J Appl Clin Med Phys; 2017 Jul; 18(4):206-214. PubMed ID: 28649722
[TBL] [Abstract][Full Text] [Related]
6. Correlation of phantom-based and log file patient-specific QA with complexity scores for VMAT.
Agnew CE; Irvine DM; McGarry CK
J Appl Clin Med Phys; 2014 Nov; 15(6):4994. PubMed ID: 25493524
[TBL] [Abstract][Full Text] [Related]
7. Phantomless patient-specific TomoTherapy QA via delivery performance monitoring and a secondary Monte Carlo dose calculation.
Handsfield LL; Jones R; Wilson DD; Siebers JV; Read PW; Chen Q
Med Phys; 2014 Oct; 41(10):101703. PubMed ID: 25281942
[TBL] [Abstract][Full Text] [Related]
8. Dose-volume and radiobiological dependence on the calculation grid size in prostate VMAT planning.
Chow JCL; Jiang R
Med Dosim; 2018 Winter; 43(4):383-389. PubMed ID: 29373184
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of one algorithm used to modify a planned DVH with data from actual dose delivery.
Ma T; Podgorsak MB; Kumaraswamy LK
J Appl Clin Med Phys; 2016 Sep; 17(5):273-282. PubMed ID: 27685140
[TBL] [Abstract][Full Text] [Related]
10. DVH analysis using a transmission detector and model-based dose verification system as a comprehensive pretreatment QA tool for VMAT plans: Clinical experience and results.
Mohamed Yoosuf AB; AlShehri S; Alhadab A; Alqathami M
J Appl Clin Med Phys; 2019 Nov; 20(11):80-87. PubMed ID: 31605456
[TBL] [Abstract][Full Text] [Related]
11. Online adaptation and verification of VMAT.
Crijns W; Defraene G; Van Herck H; Depuydt T; Haustermans K; Maes F; Van den Heuvel F
Med Phys; 2015 Jul; 42(7):3877-91. PubMed ID: 26133589
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of volumetric modulated arc therapy patient specific QA results to multileaf collimator errors and correlation to dose volume histogram based metrics.
Coleman L; Skourou C
Med Phys; 2013 Nov; 40(11):111715. PubMed ID: 24320423
[TBL] [Abstract][Full Text] [Related]
13. Development of a quasi-3D dosimeter using radiochromic plastic for patient-specific quality assurance.
Cho JD; Jin H; Jung S; Son J; Choi CH; Park JM; Kim JS; Kim JI
Med Phys; 2023 Oct; 50(10):6624-6636. PubMed ID: 37408321
[TBL] [Abstract][Full Text] [Related]
14. Moving from gamma passing rates to patient DVH-based QA metrics in pretreatment dose QA.
Zhen H; Nelms BE; Tome WA
Med Phys; 2011 Oct; 38(10):5477-89. PubMed ID: 21992366
[TBL] [Abstract][Full Text] [Related]
15. Volumetric-modulated arc therapy: effective and efficient end-to-end patient-specific quality assurance.
O'Daniel J; Das S; Wu QJ; Yin FF
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1567-74. PubMed ID: 21470797
[TBL] [Abstract][Full Text] [Related]
16. A method to reconstruct and apply 3D primary fluence for treatment delivery verification.
Liu S; Mazur TR; Li H; Curcuru A; Green OL; Sun B; Mutic S; Yang D
J Appl Clin Med Phys; 2017 Jan; 18(1):128-138. PubMed ID: 28291913
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional dose prediction and validation with the radiobiological gamma index based on a relative seriality model for head-and-neck IMRT.
Hamatani N; Sumida I; Takahashi Y; Oda M; Seo Y; Isohashi F; Tamari K; Ogawa K
J Radiat Res; 2017 Sep; 58(5):701-709. PubMed ID: 28430990
[TBL] [Abstract][Full Text] [Related]
18. Coupling I-125 permanent implant prostate brachytherapy Monte Carlo dose calculations with radiobiological models.
Miksys N; Haidari M; Vigneault E; Martin AG; Beaulieu L; Thomson RM
Med Phys; 2017 Aug; 44(8):4329-4340. PubMed ID: 28455849
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric assessment of tumor control probability in intensity and volumetric modulated radiotherapy plans.
Wang H; Cooper BT; Schiff P; Sanfilippo NJ; Wu SP; Hu KS; Das IJ; Xue J
Br J Radiol; 2019 Feb; 92(1094):20180471. PubMed ID: 30209959
[TBL] [Abstract][Full Text] [Related]
20. Using a novel dose QA tool to quantify the impact of systematic errors otherwise undetected by conventional QA methods: clinical head and neck case studies.
Chan MF; Li J; Schupak K; Burman C
Technol Cancer Res Treat; 2014 Feb; 13(1):57-67. PubMed ID: 23819494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
